Sidoti Raises Earnings Estimates for USANA Health Sciences

Key Points

• Sidoti raised its Q4 2026 EPS estimate for USANA to $0.12 from $0.11 and forecasts FY2027 EPS of $1.59.
• USANA’s latest quarter fell short of expectations: revenue was $205.9 million versus $217.4 million expected, and the company reported a $0.11-per-share loss against expected earnings of $0.11.
• The company lowered its FY2026 outlook, projecting net sales near $900 million and adjusted EBITDA of about $77 million.

USANA Health Sciences, Inc. (NYSE:USNA - Free Report) - Analysts at Sidoti raised their Q4 2026 earnings per share (EPS) estimates for shares of USANA Health Sciences in a research note issued to investors on Wednesday, November 4th. Sidoti analyst A. Lebiedzinski now anticipates that the company will post earnings of $0.12 per share for the quarter, up from their prior forecast of $0.11. The consensus estimate for USANA Health Sciences' current full-year earnings is $0.76 per share. Sidoti also issued estimates for USANA Health Sciences' Q1 2027 earnings at $0.28 EPS, Q2 2027 earnings at $0.40 EPS, Q3 2027 earnings at $0.41 EPS and FY2027 earnings at $1.59 EPS.

USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its earnings results on Tuesday, November 3rd. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.22). The company had revenue of $205.89 million during the quarter, compared to analyst estimates of $217.42 million. USANA Health Sciences had a positive return on equity of 3.55% and a negative net margin of 2.34%.

USNA has been the subject of several other research reports. Weiss Ratings restated a "sell (d)" rating on shares of USANA Health Sciences in a research report on Monday, September 21st. Zacks Research upgraded shares of USANA Health Sciences from a "strong sell" rating to a "hold" rating in a research note on Monday, October 5th. Finally, Wall Street Zen cut USANA Health Sciences from a "buy" rating to a "hold" rating in a report on Saturday, August 8th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Reduce".

USANA Health Sciences Stock Down 3.8%

USNA stock opened at $14.31 on Thursday. The stock has a market cap of $264.45 million, a PE ratio of -12.44, a price-to-earnings-growth ratio of 1.63 and a beta of 0.66. The firm's 50-day simple moving average is $14.61 and its 200 day simple moving average is $18.03. USANA Health Sciences has a fifty-two week low of $12.57 and a fifty-two week high of $23.59.

Institutional Investors Weigh In On USANA Health Sciences

Institutional investors have recently bought and sold shares of the stock. Versant Capital Management Inc lifted its stake in shares of USANA Health Sciences by 1,472.3% in the 2nd quarter. Versant Capital Management Inc now owns 1,588 shares of the company's stock worth $34,000 after acquiring an additional 1,487 shares during the period. GAMMA Investing LLC increased its stake in shares of USANA Health Sciences by 689.4% during the third quarter. GAMMA Investing LLC now owns 2,763 shares of the company's stock valued at $40,000 after acquiring an additional 2,413 shares during the period. State of Wyoming bought a new stake in USANA Health Sciences during the first quarter worth approximately $57,000. GSA Capital Partners LLP bought a new stake in USANA Health Sciences during the second quarter worth approximately $250,000. Finally, DGS Capital Management LLC bought a new stake in USANA Health Sciences during the first quarter worth approximately $208,000. Institutional investors and hedge funds own 54.25% of the company's stock.

USANA Health Sciences News Summary

Here are the key news stories impacting USANA Health Sciences this week:

• Positive Sentiment: USANA’s BiOmega omega-3 supplement again earned ConsumerLab’s Seal of Approval, providing independent validation of its quality and purity. USANA BiOmega earns ConsumerLab Seal of Approval
• Neutral Sentiment: The quarterly net loss narrowed to $5.6 million from $6.5 million a year earlier; adjusted loss per share improved to $0.11 from $0.15. USANA reports third-quarter 2026 results
• Negative Sentiment: Net sales fell 4% year over year to $206 million, below the $217.4 million analyst consensus. Adjusted EBITDA also decreased to $12.1 million from $13.8 million. The adjusted loss of $0.11 per share missed expectations for $0.11 in earnings, a sharp disappointment despite the year-over-year improvement. USANA Q3 loss narrows, sales decline and outlook lowered
• Negative Sentiment: USANA lowered its FY2026 outlook, now expecting net sales to approach $900 million and adjusted EBITDA of approximately $77 million. The reduced forecast adds to concerns about the company’s declining sales and near-term earnings performance. USANA updates sales and adjusted EBITDA outlook

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and sells nutritional supplements, healthy foods and personal-care products through a direct-selling business model. Its product portfolio includes vitamins and mineral supplements, meal-replacement and snack products, sports nutrition offerings, and skincare products marketed under the USANA and related brands.

Founded in 1992 by microbiologist and immunologist Myron W. Wentz, the company is headquartered in Salt Lake City, Utah. USANA distributes its products through a network of independent associates and preferred customers rather than primarily through traditional retail channels.

The company serves customers in markets across the Americas, Asia-Pacific and Europe, with a significant presence in countries including the United States, Canada, Australia, New Zealand, China, Hong Kong, Japan, South Korea, the Philippines, Singapore, Malaysia and Thailand.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.